Previous 10 | Next 10 |
U.S.-based gene therapy developer Genprex, Inc. is dedicated to finding more effective and novel solutions for battling cancer (particularly lung cancers) and diabetes Genprex utilizes a propriety platform that encapsulates tumor-suppressing genes within lipid nanoparticles that are injected in...
Genprex (NASDAQ: GNPX) is conducting its Phase 1/2 Acclaim-1 clinical trial evaluating the safety and efficacy of combining REQORSA(R), the company’s innovative drug candidate, in combination with Tagrisso(R) in patients with advanced EGFR mutant non-small cell lung cancer (“NSCLC&...
The positive data from the Acclaim-1 Phase 1 portion of the Phase 1/2 clinical trial has been published in an abstract at the 2023 American Society of Clinical Oncology Annual Meeting, which took place in Chicago, IL and online June 2 – 6, 2023 Acclaim-1 is an open-label, multi-center Ph...
Genprex (NASDAQ: GNPX) chief medical officer Dr. Mark Berger is spotlighted in the latest episode of the Bell2Bell podcast ( https://ibn.fm/M3OqD ). During the episode, hosted by IBN’s Jonathan Keim, the executive talks about the clinical-stage gene therapy company, which develops potenti...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the NRPL2 tumor suppressor gene. “The studies used...
2023-06-05 08:14:50 ET Bellerophon Therapeutic ( BLPH ) -71% announces top-line data from phase 3 REBUILD clinical trial of INOpulse® for treatment of fibrotic interstitial lung disease. Mallinckrodt MNK -18% to consider filing for bankruptcy again - WSJ. ...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing therapies for patients with cancer and diabetes who have limited treatment options, has released a video featuring a patient from a recent clinical trial. The patient participated in the phase 1 po...
AUSTIN, TX / ACCESSWIRE / June 2, 2023 / A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ:GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that have limited treatment options. The company is workin...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is reporting results from the phase 1 portion of its Acclaim-1 phase 1/2 clinical trial. The trial is designed to evaluate Genprex’s proprieta...
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer PR Newswire Results from Phase 1 Portion Indicate Favorable Safety P...
News, Short Squeeze, Breakout and More Instantly...
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNe...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...